ATE260090T1 - Neue suppositoriumsform mit säureempfindliche wirkstoffe - Google Patents

Neue suppositoriumsform mit säureempfindliche wirkstoffe

Info

Publication number
ATE260090T1
ATE260090T1 AT98966609T AT98966609T ATE260090T1 AT E260090 T1 ATE260090 T1 AT E260090T1 AT 98966609 T AT98966609 T AT 98966609T AT 98966609 T AT98966609 T AT 98966609T AT E260090 T1 ATE260090 T1 AT E260090T1
Authority
AT
Austria
Prior art keywords
acid
active ingredients
sensitive active
suppository form
new
Prior art date
Application number
AT98966609T
Other languages
English (en)
Inventor
Rudolf Linder
Rango Dietrich
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26042262&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE260090(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1997154324 external-priority patent/DE19754324A1/de
Priority claimed from DE1998122549 external-priority patent/DE19822549A1/de
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of ATE260090T1 publication Critical patent/ATE260090T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A61K9/025—Suppositories; Bougies; Bases therefor; Ovules characterised by shape or structure, e.g. hollow layered, coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98966609T 1997-12-08 1998-12-08 Neue suppositoriumsform mit säureempfindliche wirkstoffe ATE260090T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1997154324 DE19754324A1 (de) 1997-12-08 1997-12-08 Neue Darreichungsform enthaltend einen säurelabilen Wirkstoff
DE1998122549 DE19822549A1 (de) 1998-05-20 1998-05-20 Neue Darreichungsform enthaltend einen säurelabilen Wirkstoff
PCT/EP1998/007946 WO1999029299A1 (en) 1997-12-08 1998-12-08 Novel suppository form comprising an acid-labile active compound

Publications (1)

Publication Number Publication Date
ATE260090T1 true ATE260090T1 (de) 2004-03-15

Family

ID=26042262

Family Applications (3)

Application Number Title Priority Date Filing Date
AT98965801T ATE303809T1 (de) 1997-12-08 1998-12-08 Orale verabreichungsform enthaltend einen protonenpumpeninhbitor (z.b. pantoprazole)
AT03020043T ATE500815T1 (de) 1997-12-08 1998-12-08 Neue suppositoriumsform mit säureempfindlichem wirkstoff
AT98966609T ATE260090T1 (de) 1997-12-08 1998-12-08 Neue suppositoriumsform mit säureempfindliche wirkstoffe

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT98965801T ATE303809T1 (de) 1997-12-08 1998-12-08 Orale verabreichungsform enthaltend einen protonenpumpeninhbitor (z.b. pantoprazole)
AT03020043T ATE500815T1 (de) 1997-12-08 1998-12-08 Neue suppositoriumsform mit säureempfindlichem wirkstoff

Country Status (16)

Country Link
US (5) US6328993B1 (de)
EP (4) EP1037607B1 (de)
JP (2) JP4612184B2 (de)
AT (3) ATE303809T1 (de)
AU (2) AU748209B2 (de)
CA (2) CA2312493C (de)
DE (3) DE69842173D1 (de)
DK (2) DK1037634T3 (de)
EE (2) EE04800B1 (de)
ES (4) ES2216351T3 (de)
HU (2) HUP0100065A2 (de)
IL (3) IL136249A0 (de)
PL (2) PL195266B1 (de)
PT (1) PT1037607E (de)
SI (2) SI1037607T1 (de)
WO (2) WO1999029299A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SI1037607T1 (en) * 1997-12-08 2004-08-31 Altana Pharma Ag Novel suppository form comprising an acid-labile active compound
DE69925007T2 (de) * 1998-09-21 2006-02-02 Amato Pharmaceutical Products, Ltd., Fukuchiyama System zur oralen wirkstoffabgabe zur steigerung der bioverfügbarkeit von aktiviertem glycyrrhizin
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
WO2000074654A1 (en) * 1999-06-07 2000-12-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
KR100647901B1 (ko) * 1999-07-09 2006-11-17 보령제약 주식회사 세파클러-함유 서방성 약제조성물 및 그의 제조방법
US20060034937A1 (en) * 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
SI1341524T1 (sl) * 2000-12-07 2012-02-29 Nycomed Gmbh Farmacevtski pripravek v obliki paste, ki obsega kislinsko labilno učinkovino
CA2430824C (en) * 2000-12-07 2012-05-08 Altana Pharma Ag Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
YU61103A (sh) * 2001-02-02 2006-05-25 Teva Pharmaceutical Industries Ltd. Postupci za produkciju supstituisanih 2-(2-piridilmetil) sulfinil-1h-benzimidazola
SE0100822D0 (sv) * 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
JP4310605B2 (ja) * 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP1411900B2 (de) * 2001-06-01 2013-12-04 Pozen, Inc. Pharmazeutische zusammensetzungen für die koordinierte abgabe von nsaid
GB0120123D0 (en) * 2001-08-17 2001-10-10 Upperton Ltd Preparation of microparticles
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
JP5148813B2 (ja) * 2002-07-03 2013-02-20 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド プロトンポンプ阻害剤の液体剤形
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
AU2004220357B2 (en) 2003-03-10 2010-09-30 Astrazeneca Ab Novel process for the preparation of roflumilast
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
AR045062A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulaciones farmaceuticas para inhibir la secrecion de acido y metodos para preparar y utilizarlas
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1648417A4 (de) * 2003-07-18 2010-01-20 Santarus Inc Pharmazeutische formulierung und verfahren zur behandlung von säurebedingten gastrointestinalen erkrankungen
WO2005021056A1 (en) * 2003-08-21 2005-03-10 Cns, Inc. Effervescent delivery system
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005032554A1 (en) 2003-10-03 2005-04-14 Astron Research Pvt. Ltd A novel transmucosal delivery system
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
KR20080064209A (ko) * 2003-12-04 2008-07-08 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
AU2004294818A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
JP2007513139A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 安定性の改善した多粒子組成物
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
JP2007513145A (ja) 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 医薬用多微粒子の製造方法
EP1718303A4 (de) * 2004-02-10 2010-09-01 Santarus Inc Kombination eines protonenpumpenhemmers, puffermittels und einem nichtsteroidalen entzündungshemmenden mittel
US20050214370A1 (en) * 2004-03-26 2005-09-29 Sarama Robert J Stable coating agent comprising sterol
PL1732605T3 (pl) 2004-03-29 2019-09-30 Wyeth Llc Multiwitaminowe i mineralne suplementy odżywcze
US8968768B2 (en) * 2004-03-29 2015-03-03 Wyeth Llc Phytosterol nutritional supplements
MXPA06011820A (es) * 2004-04-16 2006-12-15 Santarus Inc Combinacion de inhibidor de bomba de proton, agente regulador del ph y agente procinetico.
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060034934A1 (en) * 2004-08-13 2006-02-16 Deguise Matthew L Agglomeration of sterol particles
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006053383A1 (en) 2004-11-22 2006-05-26 Anadis Ltd Bioactive compositions
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
ES2421916T3 (es) * 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
EP1747776A1 (de) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmazeutische Zubereitung mit granulatförmigem Pantoprazol
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2648280C (en) * 2006-04-03 2014-03-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
ES2511792T3 (es) 2006-07-25 2014-10-23 Vecta Ltd. Composiciones y métodos para la inhibición de la secreción de ácido gástrico usando derivados de pequeños ácidos dicarboxílicos en combinación con IBP
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2445499A4 (de) 2009-06-25 2013-02-27 Astrazeneca Ab Verfahren zur behandlung eines patienten mit risiko der entwicklung eines nsaid-assoziierten geschwürs
EP2338477A1 (de) 2009-12-15 2011-06-29 bene-Arzneimittel GmbH Zäpfchen mit Pantoprazol
EP2611416B1 (de) * 2010-09-03 2015-08-19 Pharmaterials Ltd. Pharmazeutische zubereitung zur verwendung in pulverinhalatoren
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2012171540A1 (en) 2011-06-15 2012-12-20 Bene-Arzneimittel Gmbh Suppository comprising pantoprazole comprised in pellets with a cellulose core
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
EP3288556A4 (de) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3544614A4 (de) 2016-11-28 2020-08-05 Lipocine Inc. Orale testosteron-undecanoat-therapie
CN117338729B (zh) * 2023-12-06 2024-02-13 山东国邦药业有限公司 一种硫氰酸红霉素可溶性颗粒及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB931147A (en) * 1959-10-23 1963-07-10 Olin Mathieson Sustained release pharmaceutical preparations and methods for their manufacture
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
DE4035455A1 (de) * 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
SE502569C2 (sv) * 1991-05-31 1995-11-13 British Tech Group Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
JPH05194225A (ja) * 1991-11-07 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
JPH05194224A (ja) * 1992-09-17 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 安定化された抗潰瘍剤含有製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
TW359614B (en) * 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
ES2145102T3 (es) * 1993-09-09 2000-07-01 Takeda Chemical Industries Ltd Formulacion que comprende una sustancia antibacteriana y una sustancia antiulcerosa.
JPH07145053A (ja) * 1993-11-25 1995-06-06 Yoshitomi Pharmaceut Ind Ltd 坐 剤
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
CA2170647C (en) * 1994-07-08 2001-03-13 Pontus John Arvid Bergstrand Multiple unit tableted dosage form i
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
GB9710800D0 (en) 1997-05-23 1997-07-23 Cipla Limited Pharmaceutical composition and method of preparing it
SI1037607T1 (en) * 1997-12-08 2004-08-31 Altana Pharma Ag Novel suppository form comprising an acid-labile active compound
SE9704869D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
DE19848849A1 (de) 1998-10-22 2000-04-27 Knoll Ag Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz

Also Published As

Publication number Publication date
ATE303809T1 (de) 2005-09-15
US6607742B2 (en) 2003-08-19
EP1037607A1 (de) 2000-09-27
IL136249A (en) 2007-07-04
DE69831504D1 (de) 2005-10-13
US20020025342A1 (en) 2002-02-28
WO1999029320A1 (en) 1999-06-17
US6383510B1 (en) 2002-05-07
CA2312493C (en) 2007-03-06
CA2310585A1 (en) 1999-06-17
SI1037634T1 (sl) 2006-02-28
IL136249A0 (en) 2001-05-20
AU2160099A (en) 1999-06-28
PL196163B1 (pl) 2007-12-31
CA2312493A1 (en) 1999-06-17
WO1999029299A1 (en) 1999-06-17
US6884437B2 (en) 2005-04-26
HUP0100065A2 (hu) 2001-08-28
DE69831504T2 (de) 2006-06-14
ES2216351T3 (es) 2004-10-16
AU748209B2 (en) 2002-05-30
JP2001525366A (ja) 2001-12-11
JP2001525355A (ja) 2001-12-11
EP1037607B1 (de) 2004-02-25
ES2249849T3 (es) 2006-04-01
US20020090397A1 (en) 2002-07-11
DE69821976T2 (de) 2004-12-16
PT1037607E (pt) 2004-07-30
DK1037634T3 (da) 2005-12-19
EE04800B1 (et) 2007-04-16
EP1037634B1 (de) 2005-09-07
EP1525882A1 (de) 2005-04-27
ES2362418T3 (es) 2011-07-05
EP1525882B1 (de) 2012-08-08
DK1037607T3 (da) 2004-06-21
US20040022854A1 (en) 2004-02-05
EP1371361B1 (de) 2011-03-09
JP4546643B2 (ja) 2010-09-15
DE69842173D1 (de) 2011-04-21
AU2413099A (en) 1999-06-28
ATE500815T1 (de) 2011-03-15
US6328993B1 (en) 2001-12-11
EP1371361A1 (de) 2003-12-17
PL341055A1 (en) 2001-03-26
DE69821976D1 (de) 2004-04-01
EE04576B1 (et) 2006-02-15
IL136285A0 (en) 2001-05-20
EP1037634A1 (de) 2000-09-27
ES2392684T3 (es) 2012-12-12
AU751066B2 (en) 2002-08-08
PL341054A1 (en) 2001-03-26
PL195266B1 (pl) 2007-08-31
US6569453B2 (en) 2003-05-27
SI1037607T1 (en) 2004-08-31
CA2310585C (en) 2005-08-23
JP4612184B2 (ja) 2011-01-12
HUP0100043A2 (hu) 2001-08-28
EE200000331A (et) 2001-08-15
EE200000329A (et) 2001-08-15

Similar Documents

Publication Publication Date Title
ATE260090T1 (de) Neue suppositoriumsform mit säureempfindliche wirkstoffe
NL194821B (nl) Farmacologisch actieve catecholderivaten en samenstellingen ervan.
FI973828A (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
DE69110785D1 (de) Narkosemittelverdampfer.
NO910923D0 (no) Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel.
DE69021713D1 (de) Förderer.
ATE71837T1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
DE68915148D1 (de) Fotoresist-zusammensetzung.
NO910874L (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinderivater.
HUP9901673A2 (hu) A politrauma utáni többszörös szervelégtelenség megakadályozására, valamint az extracorporeális vérkeringés utáni akut szerv károsodás megakadályozására szolgáló anti-szelektin antitestek
IT8920405A0 (it) Aminoimidazopiridine farmacologicamente attive.
NO913019D0 (no) Faste orale preparatformer som inneholder ifosfamid som virksomt stoff.
DE68922901D1 (de) Photoresistzusammensetzung.
DK0815141T3 (da) Antistof mod et fusionspolypeptid omfattende en histidinandel
DE68907609D1 (de) Arzneimittelzusammensetzung.
NO892871D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
DE68908838D1 (de) Pharmazeutisch wirksame Dithioketen-Derivaten.
NO911834D0 (no) Framgangsmaate for reduksjon av gassutslipp.
IT8920404A0 (it) Piperidinilimidazopiridine farmacologicamente attive.
FI884646A (fi) Foerfarande och anordning foer justering av gas och broms i en bil avsedd foer en invalid.
NO885069D0 (no) Oral komposisjon som inneholder partikler omfattende et aktivt stoff.
ATE71404T1 (de) Hybride brennstoffzusammensetzung.
NO880841L (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
ATE82138T1 (de) Geregelte verabreichungszusammensetzung.
GR1001368B (el) Φαρμακευτικοί φορείς.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1037607

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee